Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niclosamide in Resectable Colon Cancer
NCT02687009Phase 1Terminated
- Sponsor
- Michael Morse
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of niclosamide in colon cancer, sponsored by Michael Morse. Primary endpoint: Dose limiting toxicity at 5 days. Started Nov 2017; status: terminated.
02
Drugs
niclosamide
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02687009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02687009.